Direct inhibitors of FLT3.
| Compound . | Other targets . | Clinical stage . |
|---|---|---|
| AG1295 | PDGFR, KIT | Lab only |
| AG1296 | PDGFR, KIT | Lab only |
| AGL2033 | PDGFR, KIT | Lab only |
| SU5416 (sexamanib) | KIT, VEGFR | Phase 2 |
| SU5614 | KIT, FMS | Lab only |
| SU11248 (sunitinib) | KIT, PDGFR, VEGFR | Phase 1 |
| CEP-701 (lestaurtinib) | TRKA | Phase 3 |
| PKC-412 | KIT | Phase 3 |
| MLN-518 (tandutinib) | KIT, PDGFR | Phase 2 |
| CHIR-258 | KIT, FMS, VEGFR, FGFR | Phase 1 |
| BAY 43-9006 (sorafenib) | B-RAF, PDGFR, VEGFR | Lab only |
| ABT-869 | KIT, KDR, PDGFR | Phase 1 |
| Ki23819 | n/a | Lab only |
| KW-2449 | KIT, Aurora kinase | Phase 1 |
| Compound . | Other targets . | Clinical stage . |
|---|---|---|
| AG1295 | PDGFR, KIT | Lab only |
| AG1296 | PDGFR, KIT | Lab only |
| AGL2033 | PDGFR, KIT | Lab only |
| SU5416 (sexamanib) | KIT, VEGFR | Phase 2 |
| SU5614 | KIT, FMS | Lab only |
| SU11248 (sunitinib) | KIT, PDGFR, VEGFR | Phase 1 |
| CEP-701 (lestaurtinib) | TRKA | Phase 3 |
| PKC-412 | KIT | Phase 3 |
| MLN-518 (tandutinib) | KIT, PDGFR | Phase 2 |
| CHIR-258 | KIT, FMS, VEGFR, FGFR | Phase 1 |
| BAY 43-9006 (sorafenib) | B-RAF, PDGFR, VEGFR | Lab only |
| ABT-869 | KIT, KDR, PDGFR | Phase 1 |
| Ki23819 | n/a | Lab only |
| KW-2449 | KIT, Aurora kinase | Phase 1 |